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Aim: The present study aimed to demonstrate that computed tomography-guided transthoracic needle
biopsy (TTNB) is a safe procedure that gives a more accurate pre-operative tissue diagnosis for periph-
eral lung nodules than transthoracic needle aspiration, obtaining suitable samples for molecular test in
lung adenocarcinomas. Patients & methods: Between December 2016 andMarch 2018 at Thoracic Surgery
Department of the University of Palermo – Policlinico Paolo Giaccone hospital, TTNB was performed in
42 patients with computed tomography-detected peripheral lung nodules >10 mm, using 16–18-Gauge
Tru-Cut needles. Results: With TTNB, we have estimated an accuracy for tissue diagnosis of 97.6%. At the
molecular test, EGFR overexpression and ALKmutation resulted positive for 12/23 patients with lung ade-
nocarcinoma. Conclusion: TTNB has showed a low rate of complications and it is adoptable as standard
diagnostic procedure for peripheral lung nodules.
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With the increasing number of computed tomography (CT)-identified lung nodules, the most appropriate clinical
and surgical management requires a histological diagnosis [1]. The study of nodules larger than 10 mm, in order for
a medical-surgical intervention to be adopted, requires a CT-guided lung biopsy [2].
Particularly, CT-guided transthoracic needle aspiration (TTNA) and core biopsy (TTNB) are widely accepted
procedures to achieve a pre-operative tissue diagnosis for most thoracic lesions, mostly peripheral lung nodules [3].
The surgical community now agrees in preferring TTNB because of its higher number of minor complications
than TTNA (minimal pneumothorax, ground glass opacity around the target lesion). With regard to major
complications, such as pneumothorax requiring intervention (manual aspiration, chest tube placement or hospital
admission), hemothorax, air embolism and needle tract seeding, no statistically significant differences have been
observed between the two methods [4]. TTNB offers greater sensitivity, specificity and accuracy for tissue diagnosis,
for malignant lesions but especially for benign ones, but with a higher rate of minor complications, which has
emerged in various studies [3]. In addition, TTNB provides a statistically significant higher number of suitable
samples for molecular testing for lung adenocarcinomas compared with TTNA [5]. On the basis of the above, the
choice between the two methods is controversial. In this study, we present our experience in using TTNB at the
Thoracic Surgery Department of the University of Palermo – Policlinico Paolo Giaccone hospital.
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Table 1. Summary of our results, performing computed tomography-guided transthoracic needle
biopsy.
Patients n (42) Percentage
Biopsies without complications 30/42 71%
Minor complications 8/42
p  0.05
19%
p  0.05
Major complications 4/42
p  0.05
9.5%
p  0.05
Biopsies with positive diagnosis for malignancies 38/42 90.4%
Biopsies with negative diagnosis for malignancies 4/42 9.5%
False negative 1/42 2.38%
Adenocarcinoma 23/38 60.52%
Squamous cell carcinoma 11/38 28.9 %
Neuroendocrine tumor 4/38 10.5%
ALK positive 2/23 8.66%
EGFR positive 10/23 43.5%
Patients & methods
This is a retrospective analysis of 42 consecutive TTNB, performed in 42 patients admitted to our high volume
center [6] of Thoracic Surgery Department of the University of Palermo, Policlinico – Paolo Giaccone hospital
for CT-detected peripheral lung nodules >10 mm between December 2016 and March 2018. 38 TTNB were
performed using 16–18-Gauge Tru-Cut needles with cohassial technique and only 4 with 16 Gauge needles.
Specimens were fixed in formalin to undergo under tissue diagnosis and no premedication was administered before
procedure.
After tissue diagnosis, patients have been distinguished into two groups: ‘without malignancy’ and ‘with ma-
lignancy’. The last ones subdivided in two subgroups: ‘operable’ or ‘not operable’ patients. Operable patients
underwent major surgery (lobectomy, bilobectomy or pneumonectomy). After surgery, tissue diagnoses were exe-
cuted and compared with pre-operative biopsy’s histological reports. The aim was to calculate sensitivity, specificity
and accuracy of core biopsy for tissue diagnosis. Malignant specimens were tested for ALK and EGFR mutations.
Our data have been compared with clinical trials and meta-analyses found by searching on PubMed, Medline,
Embase, Web of Science and the Cochrane Library. The aim of this study is to calculate sensitivity, specificity and
accuracy of core biopsy for tissue diagnosis. Statistic evaluation of p-value has been calculated using ‘z-test’.
Results
Our results are summarized in Table 1. No complications were observed in 30 out of 42 patients after 16–18-Gauge
TTNB. Minor complications occurred in eight patients (three patients with pneumothorax and ground glass
opacity without needing a chest tube placement, and five patients with just ground glass opacities), while major
complications were observed only in four patient (pneumothorax with need of chest tube placement). It has been
estimated that TTNB presents a 19.04% of minor complications (eight patients; p < 0.05) and a 9.5% of major
ones (four patients; p < 0.05). These data are comparable with European results.
In 4 out of 42 patients, no malignancies were detected in tissue diagnosis. In 38 out of 42 patients, malignancy
was detected. Among these, 4/38 patients were inoperable: 2/4 because of comorbidities and 2/4 because of
disseminated metastasis. One out of four patients resulted with no malignancies, because of a positive positron
emission tomography (PET) examination, he underwent surgery with frozen section procedure. The intra-operative
consultation showed a positivity for adenocarcinoma. This indicates a 2.38% of false negative with core biopsy.
After histopathological exams on bioptic specimens, 23/38 patients received as diagnosis adenocarcinoma, 11
squamous cell-carcinoma and 4 neuroendocrine tumor. 34 patients underwent surgery. The definitive postoperative
histopathological exams were comparable with the pre-operative diagnosis, with a 100% of true positive.
Considering obtained tissue diagnosis for benign lesions, we have estimated a 100% of sensitivity, done!
100% of specificity and 97.6% of accuracy; while comparing pre-operative (gained by TTNB) reports with the
histopathological definitive diagnosis, we have estimated a 97.4% of sensitivity, 100% of specificity and 97.6% of
accuracy for malignancies’ tissue diagnosis.
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At our indication, on adenocarcinomas (23/42) ALK and EGFR mutations were examined, giving in 2/23
patients positive results for ALK mutation (8.66%) while in 16/23 for EGFR mutation (43.50%).
Trial design
CT-guided TTNA and core biopsy (TTNB) are widely accepted procedures to achieve a pre-operative tissue
diagnosis for most thoracic lesions, mostly peripheral lung nodules >10 mm [1,2].
Within the surgical community, it is also well known that TTNB presents the higher number of minor
complications than TTNA (minimal pneumothorax, ground glass opacity around the target lesion) [3], despite its
more reliable diagnostic power for tissue diagnosis, both in malignant and especially in benign cases. In addition,
TTNB provides more samples suitable for molecular analysis in pulmonary adenocarcinomas [5].
According to literature and AIOM 2017 guidelines, at Thoracic Surgery Department of the University of
Palermo-Policlinico Paolo Giaccone hospital, in the diagnostic management of lung cancer, after CT detection of
lung lesions, 16–18-Gauge TTNB has been performed choosing it as a standard approach, instead of TTNA, to
obtain tissue diagnosis of peripheral lung nodules>10mm, whereas endobronchial ultrasound (EBUS)-endoscopic
ultrasound (EUS) biopsy cannot reach the peripheral lung nodules or achieve a certain diagnosis, obtaining a low
rate of overall complications (summarized in Table 1). After biopsy, PET has always been executed to exclude any
false-negative results. On biopsy specimens, at our request, EGFR overexpression and ALK mutation have been
examined as molecular tests prior to surgery.
Based on this, our observational-retrospective study began with the aim of highlighting the results obtained with
TTNB, both in term of pre-operative tissue diagnosis and molecular tests on adenocarcinoma, comparing them
with those of TTNA to determine what could be the best procedure.
Our population (patients gone under TTNB at Thoracic Surgery Department of the University of Palermo-
Policlinico Paolo Giaccone hospital between December 2016 and March 2018) has been collected from operating
registers of Thoracic Surgery (as concern the technique and eventual complications) and histological reports (as
concern tissue-diagnosis and molecular testing) without ruling out any patient from the study. According to our
analyses, the sample resulted homogeneous. To confront both approaches (TTNB and TTNA), we have compared
the results observed on our population, with other data derived from the use of TTNA, selected from clinical trials
and meta-analyses with comparable populations, reachable in current literature. However, since both populations
came from different hospitals, we considered this as an operator-dependent variable, representing a limitation of
our retrospective study.
Formal trial design considerations and ethical disclosure:
• The collection of data and any other scientific experimentation have been approved by our scientific committee;
• The authors state that they have obtained institutional review board approval from Policlinico Paolo Giaccone
Hospital Scientific Committee for the research described. In addition, verbal and written informed consent has
been obtained from the patients for the inclusion of their medical and treatment history within this work.
Discussion
Pulmonary nodules are incidentally detected in around 8.5% of the general population [6] and their most appropriate
clinical and surgery management requires an histological diagnosis. For that, they represent the most common
indication for imaging-guided chest biopsy.
CT-guided TTNA and core biopsy (TTNB) are widely accepted procedures to achieve a tissue diagnosis for
most thoracic lesions, mostly peripheral lung nodules >10 mm [7].
The AIOM 2017 guidelines suggest CT examination as a necessary investigation to identify and characterize
a likely malignant lesion, and then PET-CT examination, before performing either TTNA or TTNB, thus
reducing the need to prick nonimproving solid nodules. TTNA or TTNB should be performed where EBUS-EUS
cannot reach the peripheral pulmonary nodules or arrive at a diagnosis of certainty. With PET, there is a risk of
false positives due to high glucose metabolism in cases of active inflammation (tuberculosis, histoplasmosis and
rheumatoid nodules), but also the risk of false negatives in low grade malignant tumors [8,9], such as carcinoids [10] or
low grade adenocarcinoma [11]. For this reason, we always prefer to perform nodule biopsy in our center, whenever
possible, both in the case of positive and negative PET-CT results.
Moreover, the possibility of obtaining an accurate tissue diagnosis by TTNB on peripheral pulmonary nodules,
distinguishing a primary pulmonary tumor from a distant metastasis, allows thoracic surgeons to eventually use
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new surgical techniques, alternative to traditional surgery, such as laser pulmonary metastasectomy, with which
good results could be obtained both in terms of radical resection and survival, and limiting invasive approaches on
the lung [12–14]. This notes how surgical strategy is evolving in the technological age [15].
TTNA has been proposed as a nonsurgical technique to obtain a histopathological diagnosis of suspect lung
lesions, with fewer minor complications than TTNB. Actually, according to the meta-analysis of Heerink et al. [4],
the difference between TTNA andTTNB regarding the occurrence ofminor complications is statistically significant
while it is not for major complications.
According to some studies, the main limit of TTNA is its relatively low diagnostic performance in benign lesions,
with a relatively higher false-negative rate than TTNB. In fact, patients with suspected pulmonary malignancy
undergoing cytology with TTNA often require a second surgical biopsy [16]. These data have also been confirmed
by prospective studies, such as the one drawn up by Tibel et al. [3].
Our 42 TTNB experience aims to add the accuracy, sensitivity and specificity found for tissue diagnosis, as well
as its usefulness in obtaining adequate molecular analysis samples.
The use of minimally invasive techniques such as TTNB and TTNA is preferable to obtain an adequate tumor
sample for molecular diagnosis [17]. TTNB has been shown to provide a statistically higher number of samples
suitable for molecular analysis in pulmonary adenocarcinomas than TTNA [5].
Molecular analysis is essential to identify any mutations in the tumor sample that could be used as a target for
new gene and pharmaceutical therapies. In the case of non-small-cell lung cancer (NSCLC), oncogenic factors such
as the EGFR overexpression and ALKmutation are so far, according to AIOM 2017 guidelines, the most important
predictive factor for target therapies with tyrosine kinase specific inhibitors for inoperable patients with advanced
local disease [18,19] (stage IIIB and above – TNM 2018) or patients requiring neoadjuvant therapy [20].
Clinical trials have shown significantly longer progression-free survival in patients presenting EGFR overex-
pression and therefore treated with EGFR tyrosine kinase inhibitors rather than in those undergoing first-line
chemotherapy. Similar results were observed following treatment with tyrosine kinase inhibitor, compared with
chemotherapy, in patients with ALK-rearranged [21].
This underlines the importance of both knowing the molecular condition of the cancer before any medical or
surgical intervention and the need to get to this by using the TTNB.
Thus, at our indication, on adenocarcinomas (23 out of 38 malignancies) ALKmutations and EGFR overexpres-
sion were researched. 2/23 patients resulted positive for ALKmutation (8.66%); 16/23 resulted positive for EGFR
overexpression (43.50%): these data are comparable with Global epidemiology for NSCLC [22,23]. Consequently,
according to these results, we can demonstrate that TTNB give us adequate samples for molecular testing so that
could be considered as a gold standard in evidencing targetable mutations.
Regarding the advantages in performing TTNB versus TTNA, in recent years, various retrospective and prospec-
tive studies have been drafted, focusing on the accuracy in obtaining histopathologic diagnosis in relation to minor
and major complications arising from the execution of both procedures. However, we have not found in the
literature articles comparing histopathological analysis with EGFR overexpression and ALK mutation research for
molecular analysis.
So in the end, in this context, what really represents the novelty of our study is the intention to combine the
results obtained from histopathological diagnosis with the results derived from molecular tests, to assess the overall
effectiveness of TTNB in the pre-operative diagnosis, so as to compare the data thus obtained with those present
in the literature about the two methods TTNA and TTNB.
Conclusion
Although TTNB presents more minor complications, its unquestionable tissue and molecular diagnostic capacity
allows us to look beyond these complications in order to achieve greater sensitivity, specificity and accuracy than
TTNA, both in malignant and especially benign cases, and to be able to adopt it as a standard diagnostic approach
in the study of peripheral lung nodules >10 mm.
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Summary points
Background
• Computed tomography-guided transthoracic needle aspiration and biopsy (TTNA and TTNB) are widely accepted
procedure in pre-operative diagnosis for peripheral lung nodule >10 mm.
• TTNB offers a major sensitivity, specificity and accuracy for both benign and malignant lesions than TTNA.
• With TTNB, an higher number of minor complications occurs than with TTNA. Major complications’ rate is
comparable.
• TTNB allows to obtain suitable specimens for molecular testing in pre-operative lung nodule’s diagnosis.
Methods
• 42 consecutive 16–18-Gauge TTNB were performed in 42 patients. After surgery, tissue diagnoses were executed
and compared with pre-operative biopsy’s histological reports. No complications were observed in 30 out of 42
patients, 8 patients had minor complications and 4 major complications.
• In 23 adenocarcinoma, we run molecular testing for EGFR and ALK mutations.
Results
• We have estimated that TTNB presents a 19.04% of minor complications (eight patients; p < 0.05) and a 9.5% of
major ones (four patients; p < 0.05).
• For benign lesions, we have estimated a 100, 100 and 97.6% of sensitivity, specificity and accuracy, respectively;
for malignancies, 97.4, 100 and 97.6% of sensitivity, specificity and accuracy, respectively.
• Two out of 23 patients were found positive for ALK mutation (8.66%); 16/23 were found positive for EGFR
overexpression (43.50%).
Conclusion
• TTNB offers a major tissue and molecular diagnostic capability than TTNA, showing a low rate of overall
complications, so that it could be adoptable as a standard diagnostic procedure in pre-operative diagnosis for
peripheral lung nodule >10 mm.
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